The Paradox of p53: What, How, and Why?
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Unlike the rather stereotypic image by which it was portrayed until not too many years ago, p53 is now increasingly emerging as a multifaceted transcription factor that can sometimes exert opposing effects on biological processes. This includes pro-survival activities that seem to contradict p53's canonical proapoptotic features, as well as opposing effects on cell migration, metabolism, and differentiation. Such antagonistic bifunctionality (balancing both positive and negative signals) bestows p53 with an ideal attribute to govern homeostasis. The molecular mechanisms underpinning the paradoxical activities of p53 may be related to a protein conformational spectrum (from canonical wild-type to "pseudomutant"), diversity of DNA response elements, and/or higher-order chromatin configuration. Altogether, this functional flexibility positions p53 as a transcriptional "super hub" that dictates cell homeostasis, and ultimately cell fate, by governing a hierarchy of other functional hubs. Deciphering the mechanisms by which p53 determines which hubs to engage, and how one might modulate the preferences of p53, remains a major challenge for both basic science and translational cancer medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 1×
“Thus, the celebrated “guardian of the genome” (Lane 1992) is evolving into the “guardian of homeostasis.””
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“Now, rebounding trends increasingly turn our attention to the fact that, at least in some biological contexts, p53 can actually unequivocally support cell survival, even if the beneficiary cell happens to be cancerous (Vousden and Prives 2009).”
Backgroundp53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Adipocyte differentiation from the inside out
Rosen, E. D., & MacDougald, O. A. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2066 · Cited by 2,607
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E.-L., Mizushima, N., Ohsumi, Y., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci20039 · Cited by 2,311 · cited 2×
“At first glance, autophagy appears to be a tumor suppressive mechanism, because mice heterozygous for the autophagy gene Beclin1 are tumor-prone (Qu et al. 2003; Yue et al. 2003) and Beclin 1 deletions are associated with 40%–75% of sporadic human breast, ovarian, and prostate cancers (Aita et al.…”
BackgroundYue, Z., Jin, S., Yang, C., Levine, A. J., & Heintz, N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436255100 · Cited by 2,116 · cited 2×
“…glance, autophagy appears to be a tumor suppressive mechanism, because mice heterozygous for the autophagy gene Beclin1 are tumor-prone (Qu et al. 2003; Yue et al. 2003) and Beclin 1 deletions are associated with 40%–75% of sporadic human breast, ovarian, and prostate cancers (Aita et al. 1999).”
BackgroundThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 3×
“Let us start off with apoptosis, as an example. p53 is a direct transactivator of a hoard of proapoptotic genes including BAX, the BH3-only genes PUMA and NOXA, the death receptors CD95, DR4, and DR5, and many more (Riley et al. 2008).”
BackgroundAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“The centrality of p53 for tumor suppression is dramatically illustrated by the fact that it is the most frequently mutated gene in human cancer (Petitjean et al. 2007).”
BackgroundMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 3×
“Notably, p53 pathway hyperactivation accelerates tissue deterioration and promotes the appearance of ageassociated pathologies in mice (Tyner et al. 2002; Maier et al. 2004).”
BackgroundA Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251
A high-resolution map of the three-dimensional chromatin interactome in human cells
Jin, F., Li, Y., Dixon, J. R., Selvaraj, S., Ye, Z., Lee, A. Y., Yen, C.-A., Schmitt, A. D., Espinoza, C. A., & Ren, B. (2013) · Nature · doi:10.1038/nature12644 · Cited by 1,208 · cited 1×
“The preexisting three-dimensional chromatin landscape of a particular cellular state is thought to be a stable structure that may predispose to induction of distinct sets of target genes (Jin et al. 2013).”
BackgroundRegulation of autophagy by cytoplasmic p53
Tasdemir, E., Maiuri, M. C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., D'Amelio, M., Criollo, A., Morselli, E., Zhu, C., Harper, F., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1730 · Cited by 1,132
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080 · cited 1×
“The generally accepted rationale behind these seeminglyconflicting effects of p53 is that mild ROS induces a p53-dependent growth arrest and antioxidant response, whereas excessive ROS might be conducive to p53-dependent apoptosis (Kruiswijk et al. 2015).”
Backgroundp53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810 · cited 2×
“Nevertheless, there is growing recognition that alternative p53 isoforms (Bourdon et al. 2005), derived from the TP53 gene through the usage of multiple promoters, alternative translation initiation sites, and alternative splicing, possess a diverse range of biochemical and biological activities, including cancer-prom…”
BackgroundRegeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD
Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V., & Chumakov, P. M. (2004) · Science · doi:10.1126/science.1095569 · Cited by 731
Evolution of Two-Component Signal Transduction Systems
Capra, E. J., & Laub, M. T. (2012) · Annual Review of Microbiology · doi:10.1146/annurev-micro-092611-150039 · Cited by 705
Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4149 · Cited by 633
Modulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586 · cited 2×
“Notably, p53 pathway hyperactivation accelerates tissue deterioration and promotes the appearance of ageassociated pathologies in mice (Tyner et al. 2002; Maier et al. 2004).”
BackgroundeRNAs Are Required for p53-Dependent Enhancer Activity and Gene Transcription
Melo, C. A., Drost, J., Wijchers, P. J., van de Werken, H., de Wit, E., Vrielink, J. A. F. O., Elkon, R., Melo, S. A., Léveillé, N., Kalluri, R., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.11.021 · Cited by 544
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
Wang, S.-P., Wang, W.-L., Chang, Y.-L., Wu, C.-T., Chao, Y.-C., Kao, S.-H., Yuan, A., Lin, C.-W., Yang, S.-C., Chan, W.-K., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1875 · Cited by 493
Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence
Jiang, P., Du, W., Mancuso, A., Wellen, K. E., & Yang, X. (2013) · Nature · doi:10.1038/nature11776 · Cited by 491
p53 and its mutants in tumor cell migration and invasion
Muller, P. A. J., Vousden, K. H., & Norman, J. C. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009059 · Cited by 463
Rouault, J.-P., Falette, N., Guéhenneux, F., Guillot, C., Rimokh, R., Wang, Q., Berthet, C., Moyret-Lalle, C., Savatier, P., Pain, B., et al. (1996) · Nature Genetics · doi:10.1038/ng1296-482 · Cited by 434 · cited 2×
“The canonical p21 protein is perhaps the best-documented example (Polyak et al. 1996; Janicke et al. 2008), but the list also includes others such as 14-3-3s, Plk2, Btg2, Btg3, and DDR (Rouault et al. 1996; Hermeking et al. 1997; Shimizu-Yoshida et al. 2001; Burns et al. 2003; Ongusaha et al. 2003; Ou et al. 2007).”
Backgroundp53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Fujita, K., Mondal, A. M., Horikawa, I., Nguyen, G. H., Kumamoto, K., Sohn, J. J., Bowman, E. D., Mathe, E. A., Schetter, A. J., Pine, S. R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1928 · Cited by 336 · cited 2×
“As one example, the D133p53 isoform inhibits senescence in normal human fibroblasts, whereas the p53-b isoform promotes senescence (Fujita et al. 2009).”
Backgroundp63 and p73, the ancestors of p53
Dotsch, V., Bernassola, F., Coutandin, D., Candi, E., & Melino, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004887 · Cited by 326 · cited 2×
“Although superficially binding to the same consensus sites (Dotsch et al. 2010), each member of the family has its unique gene preferences, as illustrated also by the distinct phenotypes of p53, p63, and p73 knockout mice (Murray-Zmijewski et al. 2006).”
BackgroundZhao, Y., Chaiswing, L., Velez, J. M., Batinic-Haberle, I., Colburn, N. H., Oberley, T. D., & St. Clair, D. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3835 · Cited by 245 · cited 2×
“1997; Liu and Chen 2002; Rivera and Maxwell 2005) and inhibiting G6PDH, malic enzymes, and manganese superoxide dismutase (Zhao et al. 2005; Jiang et al. 2011, 2013).”
BackgroundProapoptotic BID Is an ATM Effector in the DNA-Damage Response
Kamer, I., Sarig, R., Zaltsman, Y., Niv, H., Oberkovitz, G., Regev, L., Haimovich, G., Lerenthal, Y., Marcellus, R. C., & Gross, A. (2005) · Cell · doi:10.1016/j.cell.2005.06.014 · Cited by 226
Liu, G., & Chen, X. (2002) · Oncogene · doi:10.1038/sj.onc.1205862 · Cited by 207
The Utility of Paradoxical Components in Biological Circuits
Hart, Y., & Alon, U. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.004 · Cited by 151 · cited 2×
“In other words, for bacteria, changes in the concentration of any of the components will not change the phosphorylation– dephosphorylation ratio (Hart and Alon 2013).”
BackgroundRegulation of the p53 transcriptional response by structurally diverse core promoters
Morachis, J. M., Murawsky, C. M., & Emerson, B. M. (2010) · Genes & Development · doi:10.1101/gad.1856710 · Cited by 86
Removing all obstacles: A critical role for p53 in promoting tissue renewal
Schoppy, D. W., Ruzankina, Y., & Brown, E. J. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11194 · Cited by 32 · cited 1×
“Indeed, numerous studies support the notion that p53 inhibits cell migration, tissue renewal, and wound healing (Tyner et al. 2002; Schoppy et al. 2010; Muller et al. 2011).”
Background
Cited by
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway
Furth, N., & Aylon, Y. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.99 · Cited by 260
Self-citationTargeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
“As such, it also provides the differential toxicity observed with therapies between normal cells and cancer cells, leading to cell death upon treatment (Aylon & Oren 2016).”
Background
Metadata
- Authors
- Aylon, Y., & Oren, M.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-07-13
- Volume
- 6
- Issue
- 10
- Pages
- a026328
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2462696588
- Cited by
- 79
- References
- 36
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.